Inside the research

Integra LifeSciences Holdings Corporation

IART Research profile · latest available data

Price overview

$16.27

▲ +0.15 (+0.9%)

52w hi$19.85
52w lo$8.90
Vol479.03K
As of28 Sep 2026

The Verdict

Hold

Our score -0.14

Short-0.21
Medium-0.04
Long-0.20

computed 2026-09-28

Key fundamentals

Integra LifeSciences Holdings Corporation

Healthcare · Medical Devices

Market cap$1.27B
Enterprise value$3.03B
Forward P/E6.24x
EV / EBITDA9.56x
P / S (ttm)0.77x
Profit margin-0.4%
Return on equity-0.7%
Revenue growth+0.8%
Debt / equity196.49

Layer Breakdown

LayerRawContribution
Fundamental+0.06
Sector+0.09
Technical-0.16
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-28

Business overview

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

United States · www.integralife.com

Risk Metrics

Beta vs SPX1.45
Corr SPX0.38
Annual vol60.9%
Annual ret+14.8%
Sharpe0.24
Max DD-66.7%

Window: 504 trading days (504 obs)

Material Events

DateEvent8-K
2026-07-29Earnings Release, Exhibitsread
2026-05-08Officer / Director Change, Shareholder Vote…read
2026-05-05Officer / Director Change, Exhibitsread
2026-05-05Earnings Release, Exhibitsread
2026-04-15Material Agreementread
2026-02-26Earnings Release, Exhibitsread
2025-12-12Officer / Director Change, Exhibitsread
2025-10-30Earnings Release, Exhibitsread
2025-07-31Earnings Release, Exhibitsread
2025-06-09Material Agreement, Material Obligation…read
2025-05-13Officer / Director Change, Shareholder Vote…read
2025-05-05Earnings Release, Exhibitsread

Insider Trades

DateInsiderRoleActionSharesValue
2026-07-03Knight Lea DanielsEVP & Chief Financial OffWithheld for tax5.23K$94.33K
2026-07-01Mosebrook JeffreySVP, Fin & Princ Acct OffWithheld for tax937$16.76K
2026-05-09BRADLEY KEITHWithheld for tax882$12.28K
2026-05-07HILL BARBARA BGrant6.64K—
2026-05-07HILL BARBARA BGrant17.70K—

Flow & Concentration

Insider 180d net$0
Insider buys / sells0 / 0
Insider biasNeutral
13F holders7
Top-5 share99.9%
HHI4,708 (concentrated)

Top Holders

HolderValueShares
State Street Corp$52.93M2.95M
Millennium Management$25.86M1.44M
AQR Capital Management$4.64M258.16K
Capital Research / Capital World$2.48M138.32K
Renaissance Technologies$188.58K10.50K
Fidelity / FMR LLC$92.33K5.14K
T. Rowe Price Group$1.65K91.92K

As of 2026-06-30

SEC Filings

DateFormDoc
2026-07-2910-Qview
2026-07-298-Kview
2026-07-064view
2026-07-064view
2026-07-064view
2026-07-064view
2026-06-034view
2026-06-034view
2026-05-114view
2026-05-114view
2026-05-114view
2026-05-114view
2026-05-114view
2026-05-114view
2026-05-088-Kview

The Long Run

FY 2010–2025 · 16 years

LineLatestCAGRTrend
Revenue$1.61B+5.4%
Gross profit$230.78M+7.9%
Operating income-$493.37M+7.6%
Net income-$516.47M+10.2%
Cash from ops$50.38M-2.4%

Indices

S&P SmallCap 600

Recent Sessions

DateOpenHighLowCloseVol
Sep 28$15.99$16.27$15.86$16.27479.03K
Sep 25$15.88$16.21$15.74$16.12539.00K
Sep 24$15.67$15.91$15.49$15.88759.50K
Sep 23$15.88$16.26$15.38$15.53573.10K
Sep 22$15.90$16.29$15.69$16.02770.50K

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →